Literature DB >> 24666179

Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial.

Michelle Furtado1, Martin J S Dyer, Rod Johnson, Margie Berrow, Simon Rule.   

Abstract

Entities:  

Keywords:  CD20 antibody; mantle cell lymphoma; ofatumumab

Mesh：

Substances：

Year:  2014        PMID： 24666179     DOI： 10.1111/bjh.12769

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

1.  Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.

Authors:  Alice Bonanni; Enrica Bertelli; Andrea Moscatelli; Elisabetta Lampugnani; Monica Bodria; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2016-06-28       Impact factor: 4.335

2.  Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors:  Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

3.  Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.

Authors:  Matthew J Barth; Cory Mavis; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri
Journal:  Clin Cancer Res       Date:  2015-05-11       Impact factor: 12.531

Review 4.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 5.  Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Authors:  Fengting Yan; Ajay K Gopal; Solomon A Graf
Journal:  Pharmaceuticals (Basel)       Date:  2017-03-10

6.  Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.

Authors:  Marie Viala; Marie Vinches; Marie Alexandre; Caroline Mollevi; Anna Durigova; Nadia Hayaoui; Krisztian Homicsko; Alice Cuenant; Céline Gongora; Luca Gianni; Diego Tosi
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

7.  New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.

Authors:  Andreea Lucia Stancu; Mitchell R Smith; Alexandru Almasan
Journal:  Discoveries (Craiova)       Date:  2014 Jan-Mar

Review 8.  Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes.

Authors:  Nishanth Vallumsetla; Jonas Paludo; Prashant Kapoor
Journal:  Ther Clin Risk Manag       Date:  2015-11-06       Impact factor: 2.423

Review 9.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

Review 10.  Current trials for frontline therapy of mantle cell lymphoma.

Authors:  Raphael E Steiner; Jorge Romaguera; Michael Wang
Journal:  J Hematol Oncol       Date:  2018-01-27       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.